Worldwide: Life Sciences, Biotechnology & Nanotechnology

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Health Care Fraud And Qui Tam Actions Under The False Claims Act: Avoiding The Government’s Crosshairs
Federal enforcement of Medicare and Medicaid fraud has intensified dramatically, with recent prosecutions involving billions in alleged losses and sophisticated data analytics. Recent Sixth Circuit decisions reveal critical compliance vulnerabilities in medical necessity documentation, billing practices, and compensation structures that can trigger both criminal prosecution and civil False Claims Act liability.
United States Healthcare
FB
FBT Gibbons
Article
FDA Approves First Gene Therapy For Rare Pediatric Immune Disorder Severe Leukocyte Adhesion Deficiency Type I
The FDA has approved Kresladi, a groundbreaking gene therapy that uses patients' own genetically modified blood stem cells to treat severe Leukocyte Adhesion Deficiency Type I, a rare inherited immune disorder that leaves children vulnerable to life-threatening infections. This first-of-its-kind treatment offers an alternative to risky blood stem cell transplants, particularly for patients without matched sibling donors.
United States Healthcare
GP
Goodwin Procter LLP
Article
Federal District Court Blocks Texas AG Ken Paxton From Enforcing Conspicuous Warning Label Requirement For Food Products Containing 44 Listed Ingredients
In 2025, Texas passed Senate Bill 25, which includes a labeling mandate for food products. Section 9 of the Bill adds language to the Texas Health and Safety Code that would require food manufacturers to put conspicuous warning labels on any food product sold in the State that contains any of 44 listed ingredients (subject to some exceptions).
United States Healthcare
SJ
Steptoe LLP
Article
Developments In Securities Fraud Class Actions Against U.S. Life Sciences Companies
Last year marked a decrease in federal securities class action filings, with plaintiffs filing 207 cases in 2025, down from 225 in 2024. However, life sciences companies remained popular targets, accounting for 47 of these filings.1 In this White Paper, we examine 2025's filing and decision trends and provide insights to help life sciences companies navigate the litigation landscape prudently.
United States Commercial
D
Dechert
See more